Study guide

12.3 Viscoelastic Hemostatic Assays (TEG/ROTEM) & Tranexamic Acid (TXA)

BCEN TCRN Trauma Certified Registered Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Head & Neck Trauma I - Traumatic Brain Injury & ICP

1.1 Primary vs. Secondary Brain Injury & Pathophysiology 1.2 Intracranial Pressure (ICP) Monitoring & Monroe-Kellie Doctrine 1.3 Cerebral Perfusion Pressure (CPP) & Medical Management of Elevated ICP 1.4 Herniation Syndromes & Acute Surgical TBI Interventions

2 Chapter 2: Head & Neck Trauma II - Maxillofacial, Ocular & Spinal Cord Trauma

2.1 Maxillofacial Trauma & Airway Management (Le Fort & Mandibular Fractures) 2.2 Ocular Trauma Assessment & Emergency Interventions 2.3 Penetrating & Blunt Neck Trauma (Zone I-III Management) 2.4 Cervical & Upper Spinal Cord Injury (Neurogenic Shock vs. Spinal Shock & ASIA Scale)

3 Chapter 3: Thoracic Trauma I - Immediate Life-Threatening Airway & Chest Injuries

3.1 Tension Pneumothorax, Simple Pneumothorax & Needle Decompression 3.2 Open Pneumothorax & Massive Hemothorax Management 3.3 Cardiac Tamponade & Resuscitative Thoracotomy Indications 3.4 Tracheobronchial Disruption & Flail Chest with Pulmonary Contusion

4 Chapter 4: Thoracic Trauma II - Vascular, Parenchymal & Diaphragmatic Injuries

4.1 Blunt Cardiac Injury (BCI) & Myocardial Contusion Monitoring 4.2 Traumatic Aortic Disruption (TAD) & Great Vessel Injury 4.3 Esophageal Perforation & Penetrating Thoracic Trauma 4.4 Diaphragmatic Rupture & Thoracic Surgical Indications

5 Chapter 5: Abdominal Trauma - Solid Organ, Hollow Viscus & Abdominal Compartment Syndrome

5.1 Hepatic & Splenic Trauma Grading & Non-Operative Management 5.2 Hollow Viscus & Mesenteric Injury (Bowel Perforation & Peritonitis) 5.3 FAST Exam, Diagnostic Peritoneal Lavage (DPL) & Abdominal CT Indications 5.4 Retroperitoneal Hemorrhage & Abdominal Compartment Syndrome (ACS)

6 Chapter 6: Pelvic & Genitourinary Trauma

6.1 Pelvic Fracture Classification & Biomechanical Instability 6.2 Acute Pelvic Hemorrhage Control (Pelvic Binders, Angiography & REBOA) 6.3 Bladder & Urethral Trauma (High-Riding Prostate & Retrograde Urethrography) 6.4 Renal & Ureteral Trauma Management

7 Chapter 7: Musculoskeletal Extremity Trauma & Compartment Syndrome

7.1 Open Fractures & Gustilo-Anderson Classification 7.2 Traumatic Amputations & Mangled Extremity Severity Score (MESS) 7.3 Extremity Vascular Injury (Hard vs. Soft Signs & Ankle-Brachial Index) 7.4 Compartment Syndrome & Fasciotomy Indications

8 Chapter 8: Wound Care, Soft Tissue & Burn Trauma

8.1 Soft Tissue Trauma, Crush Injury & Rhabdomyolysis 8.2 Burn Depth Assessment & Total Body Surface Area (TBSA) Calculation 8.3 Parkland Formula & Fluid Resuscitation Protocols for Burns 8.4 Inhalation Injury, Escharotomy & Burn Wound Care

9 Chapter 9: Special Populations I - Pediatric & Geriatric Trauma

9.1 Pediatric Trauma Airway, Breathing & Physiologic Differences 9.2 Pediatric Fluid Resuscitation, Vital Signs & Child Abuse/NAT Recognition 9.3 Geriatric Trauma Physiology, Frailty & Medication Effects (Anticoagulants/Beta Blockers) 9.4 Geriatric Rib Fractures, Fall Mechanisms & Traumatic Brain Injury

10 Chapter 10: Special Populations II - Pregnancy, Bariatric & Vulnerable Populations

10.1 Pregnant Trauma Patient Physiologic Adaptation & Supine Hypotensive Syndrome 10.2 Fetal Assessment, Kleihauer-Betke Test & Perimortem Cesarean Delivery 10.3 Bariatric Trauma Considerations & Airway/Resuscitation Challenges 10.4 Intimate Partner Violence, Human Trafficking & Substance Use in Trauma

11 Chapter 11: Initial Trauma Assessment & Airway Management

11.1 Triage Systems & Trauma Center Levels I-IV 11.2 Primary Survey (ABCDE) & Rapid Trauma Assessment 11.3 Airway Management & Rapid Sequence Intubation (RSI) in Trauma 11.4 Secondary Survey (FGHIJ) & AMPLE History Collection

12 Chapter 12: Trauma Shock & Damage Control Resuscitation

12.1 Pathophysiology & Classification of Shock in Trauma 12.2 Massive Transfusion Protocol (MTP) & Balanced 1:1:1 Blood Product Resuscitation 12.3 Viscoelastic Hemostatic Assays (TEG/ROTEM) & Tranexamic Acid (TXA) 12.4 Damage Control Resuscitation, Permissive Hypotension & Lethal Triad Prevention

13 Chapter 13: Post-Resuscitation Critical Care & Complications

13.1 Acute Respiratory Distress Syndrome (ARDS) in Trauma 13.2 Disseminated Intravascular Coagulation (DIC) & Trauma-Induced Coagopathy (TIC) 13.3 Systemic Inflammatory Response Syndrome (SIRS), Sepsis & MODS 13.4 Invasive Hemodynamic Monitoring & Hypothermia Prevention

14 Chapter 14: Rehabilitation, Psychosocial Support & Transition of Care

14.1 Acute Stress Response, PTSD Screening & Trauma Psychosocial Support 14.2 Family-Centered Care & End-of-Life/Brain Death Determination 14.3 Organ Donation Protocols & Donor Management in Trauma 14.4 Inter-Facility Transfer Protocols (EMTALA/COBRA) & Discharge Planning

15 Chapter 15: Professional Practice, Quality & Disaster Management

15.1 Trauma Registry & Performance Improvement and Patient Safety (PIPS) 15.2 Mass Casualty Triage (START/JumpSTART) & Incident Command System (ICS) 15.3 Legal, Ethical & Forensic Evidence Preservation in Trauma Nursing 15.4 Secondary Traumatic Stress, Nurse Resilience & Team Well-being

12.3 Viscoelastic Hemostatic Assays (TEG/ROTEM) & Tranexamic Acid (TXA)

Key Takeaways Explain This Topic AI

Viscoelastic assays (TEG/ROTEM) provide real-time point-of-care whole blood dynamic analysis of clot initiation, strength, and lysis.

TEG R-time prolongation (> 10 min) requires FFP/PCC; low Alpha angle/K-time requires Cryoprecipitate; low MA requires Platelets; elevated LY30 requires TXA.

ROTEM FIBTEM isolates functional fibrinogen levels by pharmacological inhibition of platelets using cytochalasin D.

Tranexamic Acid (TXA) is a synthetic lysine analog that competitively inhibits plasminogen activation to prevent fibrinolysis.

CRASH-2 trial proves TXA reduces mortality when given < 3 hours post-injury; dosing is 1g IV bolus over 10 min followed by 1g IV over 8 hours.

Last updated: July 2026

12.3 Viscoelastic Hemostatic Assays (TEG/ROTEM) & Tranexamic Acid (TXA)

Trauma-Induced Coagulopathy (TIC) occurs in up to 35% of severely injured trauma patients upon arrival and is driven by tissue trauma, hypoperfusion, systemic anti-coagulation, consumption of clotting factors, and hyperfibrinolysis. Traditional laboratory coagulation tests (Prothrombin Time [PT], International Normalized Ratio [INR], activated Partial Thromboplastin Time [aPTT], and static plasma fibrinogen levels) are inadequate in acute resuscitation because they are performed on cell-free plasma at 37 degrees C, take 45 to 60 minutes to return, and only evaluate initial fibrin formation. Viscoelastic Hemostatic Assays (VHA)—specifically Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM)—provide rapid, real-time, point-of-care evaluation of whole blood coagulation mechanics from initial clot formation through clot strength and fibrinolysis, guiding targeted hemostatic therapy.

Mechanics of Viscoelastic Testing (TEG vs. ROTEM)

Viscoelastic assays measure the viscoelastic properties of whole blood as it clots under shear stress:

TEG Technology: A pin is suspended into an oscillating cylindrical cup containing a whole blood sample. As fibrin-platelet strands form between the cup wall and the pin, torque is transmitted to the pin and converted into a characteristic graphic tracing.

ROTEM Technology: The cup remains stationary while an optical pin oscillates within the blood sample. ROTEM utilizes specific automated channels (EXTEM, INTEM, FIBTEM, APTEM) to isolate extrinsic pathways, intrinsic pathways, fibrinogen contribution, and hyperfibrinolysis.

TEG Parameters, Clinical Interpretations, and Targeted Hemostatic Therapies

Viscoelastic testing allows the trauma resuscitation team to transition from empiric 1:1:1 transfusion to goal-directed component therapy based on specific numeric parameters:

1. Reaction Time (R-Time) / ROTEM Clotting Time (CT)

Definition: Time (in minutes) from test initiation until initial fibrin formation occurs (amplitude reaches 2 mm).

Normal TEG Value: 5.0 to 10.0 minutes.

Clinical Interpretation: Reflects the activity and concentration of soluble coagulation cascade factors (intrinsic and extrinsic pathways).

Targeted Treatment: A prolonged R-time (> 10 minutes) indicates clotting factor deficiency. The indicated intervention is administration of Fresh Frozen Plasma (FFP, typically 2 to 4 units) or Prothrombin Complex Concentrate (PCC).

2. K-Time and Alpha Angle (α-Angle) / ROTEM Clot Formation Time (CFT) and Alpha Angle

Definition: K-time is the time from R-time until clot amplitude reaches 20 mm. Alpha angle measures the slope of the tracing tangent to the expanding clot curve.

Normal TEG Values: K-time = 1.0 to 3.0 minutes; Alpha Angle = 53 to 72 degrees.

Clinical Interpretation: Evaluates the rate of clot kinetics and propagation, primarily dependent on fibrinogen availability and cleavage into fibrin strands.

Targeted Treatment: A prolonged K-time (> 3 minutes) or decreased Alpha Angle (< 53 degrees) signifies low functional fibrinogen. The indicated intervention is administration of Cryoprecipitate (typically 10 to 20 units or 1 to 2 donor pools) or Fibrinogen Concentrate (Riastap/Fibryga).

3. Maximum Amplitude (MA) / ROTEM Maximum Clot Firmness (MCF)

Definition: The maximum width/height (in millimeters) of the TEG tracing.

Normal TEG Value: 50 to 70 mm.

Clinical Interpretation: Represents ultimate structural clot strength and rigidity. Clot strength is determined 80% by platelet count and function (platelet-fibrinogen cross-linking via GPIIb/IIIa receptors) and 20% by fibrinogen.

Targeted Treatment: A decreased MA (< 50 mm) indicates severe platelet deficiency or dysfunction. The indicated intervention is administration of Platelets (1 apheresis unit). If the patient is on antiplatelet agents (e.g., aspirin, clopidogrel), Desmopressin (DDAVP 0.3 mcg/kg IV) may be co-administered to stimulate von Willebrand factor release.

4. Lysis at 30 Minutes (LY30) / ROTEM Maximum Lysis (ML)

Definition: The percentage decrease in clot amplitude 30 minutes after MA is achieved.

Normal TEG Value: 0.0% to 3.0%.

Clinical Interpretation: Measures the rate of clot breakdown (fibrinolysis). Elevated LY30 (> 3.0%) indicates pathologically accelerated clot dissolution, known as hyperfibrinolysis.

Targeted Treatment: An elevated LY30 indicates hyperfibrinolysis driven by tissue plasminogen activator (tPA) surge. The immediate indicated intervention is administration of an antifibrinolytic agent, specifically Tranexamic Acid (TXA) or Aminocaproic Acid.

ROTEM FIBTEM Utility

ROTEM includes a specialized assay (FIBTEM) that uses cytochalasin D to irreversibly inhibit platelets. The resulting clot firmness (FIBTEM MCF) reflects purely functional fibrinogen concentration, allowing rapid differentiation between fibrinogen deficiency (FIBTEM MCF < 10 mm) and platelet deficiency without waiting for full MA results.

Tranexamic Acid (TXA): Pharmacodynamics and Clinical Evidence

Tranexamic Acid (TXA) is a synthetic derivative of the amino acid lysine that acts as a potent antifibrinolytic agent.

Mechanism of Action

TXA competitively binds to the lysine-binding sites on plasminogen molecules. By blocking these sites, TXA prevents plasminogen from binding to fibrin surface strands, thereby inhibiting the activation of plasminogen into plasmin. Without plasmin, enzymatic degradation of stable fibrin clots (fibrinolysis) is halted, preserving early hemostatic plugs at injury sites.

Landmark Clinical Trial Evidence: CRASH-2 and CRASH-3

CRASH-2 Trial: Evaluated over 20,000 adult trauma patients with significant hemorrhage or risk of hemorrhage. Demonstrated that early administration of TXA significantly reduced all-cause mortality and bleeding-related mortality without increasing thromboembolic events (DVT, PE, stroke, MI). Crucially, sub-analysis proved that TXA administered within 1 hour of injury yielded maximum benefit, and administration between 1 and 3 hours post-injury remained beneficial. However, TXA administered more than 3 hours after injury resulted in increased mortality and heightened risk of fatal thrombosis.

CRASH-3 Trial: Investigated TXA in traumatic brain injury (TBI). Demonstrated that early TXA administration (< 3 hours) reduced 28-day head injury-related mortality in mild-to-moderate TBI (GCS 9-14), confirming intracranial antifibrinolytic benefit.

Standard Trauma Dosing Protocol

Initial Bolus: 1 gram of Tranexamic Acid diluted in 100 mL of 0.9% Normal Saline or Lactated Ringer's, administered IV piggyback over 10 minutes (infusing faster than 10 minutes may cause transient hypotension). Must be initiated within 3 hours of injury.

Maintenance Infusion: 1 gram of TXA infused IV over the subsequent 8 hours.